Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VST-1001 for Lymphatic Mapping in Breast Cancer
NCT02294565Phase 2Unknown
- Sponsor
- Vestan
- Start
- Jun 2014
- Primary completion
- Jan 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fluorescein in breast cancer, sponsored by Vestan. Primary endpoint: Lymph Node-Level Concordance of Visually Observed VST-1001 Fluorescence and 99mTc-Labeled Sulfur Colloid Radioactivity. Status: unknown.
02
Drugs
fluorescein
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02294565.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02294565.